%20(2).png)
About
.png)
Black Cat Bio Limited is a UK-based private limited company established in 2020 by Stephen Wolstenhulme (CEO) and Chen Zhang (CSO). The company was originally formed to explore multiple commercial avenues but has since been streamlined with a focused mission in animal health, aiming to develop and advance high-value veterinary biotechnology solutions.
Today, the company’s core focus is the development and commercialization of next-generation animal health technologies, with its most advanced intellectual property centered on CS20, a bivalent Type I & Type II PRRSV live vaccine platform designed to address one of the most economically significant diseases in global swine production.
CS20 Vaccine Development Background
The CS20 platform originated through long-standing scientific collaboration and discussion between the inventor and Chen Zhang, who have maintained a professional relationship for many years and are both based in China. This collaboration led to the conceptualization of a dual-strain vaccine approach targeting both major PRRSV genotypes.
Following over a decade of prior research in this field by the inventor, the first live pig study (Experiment 1, E1) was conducted in 2020. While the study generated promising early results, the progression of the work was disrupted due to the COVID-19 pandemic, which prevented full completion of the experimental protocol.
As a result, E1 produced partial but encouraging data supporting the potential of the CS20 approach. Based on these findings, there is now a strong scientific and commercial rationale to complete a follow-up 3–4 month second challenge study (Experiment 2, E2) in live piglets. This next phase is intended to validate immune efficacy, strengthen the existing E1 dataset, and complete the full scientific and regulatory evidence package for CS20.
